Department of Gastroenterology, Kochi Medical School, Kochi, Japan.
Università degli Studi di Firenze, Polo Scientifico, Laboratorio di Chimica Bioinorganica, Rm. 188, Via della Lastruccia 3, 50019 Sesto Fiorentino (Florence), Italy.
Bioorg Med Chem Lett. 2014 Feb 15;24(4):1127-32. doi: 10.1016/j.bmcl.2013.12.124. Epub 2014 Jan 8.
We investigated the cloning, catalytic activity and anion inhibition of the β-class carbonic anhydrases (CAs, EC 4.2.1.1) from the bacterial pathogen Legionella pneumophila. Two such enzymes, lpCA1 and lpCA2, were found in the genome of this pathogen. These enzymes were determined to be efficient catalysts for CO2 hydration, with kcat values in the range of (3.4-8.3)×10(5) s(-1) and kcat/KM values of (4.7-8.5)×10(7) M(-1) s(-1). A set of inorganic anions and small molecules was investigated to identify inhibitors of these enzymes. Perchlorate and tetrafluoroborate were not acting as inhibitors (KI >200 mM), whereas sulfate was a very weak inhibitor for both lpCA1 and lpCA2 (KI values of 77.9-96.5 mM). The most potent lpCA1 inhibitors were cyanide, azide, hydrogen sulfide, diethyldithiocarbamate, sulfamate, sulfamide, phenylboronic acid and phenylarsonic acid, with KI values ranging from 6 to 94 μM. The most potent lpCA2 inhibitors were diethyldithiocarbamate, sulfamide, sulfamate, phenylboronic acid and phenylarsonic acid, with KI values ranging from 2 to 13 μM. As these enzymes seem to be involved in regulation of phagosome pH during Legionella infection, inhibition of these targets may lead to antibacterial agents with a novel mechanism of action.
我们研究了细菌病原体嗜肺军团菌的β 类碳酸酐酶(CA,EC 4.2.1.1)的克隆、催化活性和阴离子抑制作用。在这种病原体的基因组中发现了两种这样的酶,lpCA1 和 lpCA2。这些酶被确定为 CO2 水合的有效催化剂,kcat 值在(3.4-8.3)×10(5) s(-1)范围内,kcat/KM 值为(4.7-8.5)×10(7) M(-1) s(-1)。一组无机阴离子和小分子被用来鉴定这些酶的抑制剂。高氯酸盐和四氟硼酸盐没有表现出抑制作用(KI >200 mM),而硫酸盐对 lpCA1 和 lpCA2 都是非常弱的抑制剂(KI 值分别为 77.9-96.5 mM)。lpCA1 的最有效抑制剂是氰化物、叠氮化物、硫化氢、二乙二硫代氨基甲酸盐、氨基磺酸酯、磺胺、苯硼酸和苯胂酸,KI 值范围为 6-94 μM。lpCA2 的最有效抑制剂是二乙二硫代氨基甲酸盐、磺胺、氨基磺酸酯、苯硼酸和苯胂酸,KI 值范围为 2-13 μM。由于这些酶似乎参与了军团菌感染期间吞噬体 pH 的调节,抑制这些靶标可能会导致具有新型作用机制的抗菌剂。